Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 501 - 510 of 785 studies

Eye Neurological

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Cancer and neoplasms

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas (EMBOLD Sarcoma‑202)

Who cares for the caregiver? Developing approaches to support caregivers in the CAR-T ambulatory care setting: a qualitative narrative study

Neurological

A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis

Cancer and neoplasms

A Phase 1/2, Multicenter, First in Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements

STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b/tsDMARD) Exposure in Psoriatic Arthritis (STRIDE-PsA)

Blood

Initial Safety and Efficacy, Sequential Group, Adaptive Dose Study of GL-2045 Subcutaneous Injection Repeat Doses in Patients with Immune Thrombocytopenia GL-2045-03 (GL-2045-03)

Blood Reproductive health and childbirth

A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult Female Patients with Von Willebrand Disease (VWD) (HMBeacon)

Cancer and neoplasms

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer. (CA2660003 (ROSETTA CRC-203))

Oral and Gastrointestinal

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease